Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 60

Results For "products"

2384 News Found

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer
People | December 14, 2024

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines


Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Drug Approval | December 14, 2024

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months


CuraTeQ Biologics receives positive opinion for biosimilar Zefylti
Drug Approval | December 14, 2024

CuraTeQ Biologics receives positive opinion for biosimilar Zefylti

Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells


Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion
Supply Chain | December 12, 2024

Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion

Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain


LVMH Recherche and Integrated Biosciences partner to discover anti-aging chemical entities
News | December 10, 2024

LVMH Recherche and Integrated Biosciences partner to discover anti-aging chemical entities

Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging


Laurus Labs invests in Laurus Bio
News | December 09, 2024

Laurus Labs invests in Laurus Bio


Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease
Biotech | December 07, 2024

Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease

GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization


FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy
Drug Approval | December 07, 2024

FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy

Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients